Find out why doctors can’t prescribe your brand, and what you can do about it
Market barriers affect a staggering 37% of prescriptions for oral treatments for Type 2 Diabetes Mellitus in the US. According to the diabetologists and primary care physicians we surveyed, that’s a problem with no single solution. Many of them experience as many as 2 different barriers with any given brand, and for some brands that grows to 3.
Find out which barriers cost your brand the most market share, which competitors are taking it from you, and what you can do to win it back, in Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US).
Based on a survey of 100 diabetologists and primary care physicians, the report covers 9 major oral therapies from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck & Co. and Takeda. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Reasons to Purchase
Big barriers, big problems. US physicians claim that close to 40% of all oral diabetes therapy prescriptions are impacted by barriers; find out what’s the biggest barrier, and if anything can be done about it
Despite the barriers, treatment usage is high. Find out which brands get used a lot despite the prescribing restrictions, and which ones lose out
One barrier to rule them all. Between 35-60% of surveyed doctors experience this one barrier for all treatment options; what is it and can anything be done to lower its impact?
Market access mistakes could be costing some brands dear. Another barrier impacts 25-55% of prescriptions, and market access mistakes could be the key reason.
In a barrier free world, one brand could lose out…big time. One brand takes market share from several other brands, but if restrictions were lifted physicians predict usage could plummet. Is it your brand?
Insight into 9 Major Oral Type 2 Diabetes Mellitus Treatments
Farxiga (dapagliflozin; AstraZeneca)
Glyxambi (empagliflozin/linagliptin; Eli Lilly/Boehringer Ingelheim)
Invokana (canagliflozin; Johnson & Johnson)
Januvia (sitagliptin; Merck & Co.)
Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
Nesina (alogliptin; Takeda)
Onglyza (saxagliptin; AstraZeneca)
Qtern (saxagliptin/dapagliflozin; AstraZeneca)
Tradjenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
Exploring Market Access Barriers
Market Access Impact: Type 2 Diabetes Mellitus (Orals) (US) explores key issues affecting drug manufacturers. You’ll learn:
How barriers affect market access:
What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?
How barriers affect your brand:
How many doctors prescribe your brand? How many don’t, but would consider it?
Why don’t doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 US-based diabetologists and primary care physicians, chosen from the largest community of validated physicians in the world
Have been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients in total in the last month
We conducted the survey between November 6-15, 2017.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.